BSX vs REPL · P/E 20, rev $16.75B vs $825.7M cap
Boston Scientific Corp (BSX) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Boston Scientific Corp (BSX) is a medical devices company listed on US.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported BSX revenue for 2024-12-31 was $16.75B. Net income was $1.85B. Revenue was up 17.6% from 2023-12-31 to 2024-12-31. BSX currently screens at market cap $71.81B and trailing P/E 20.2.
REPL does not have a complete income-statement cache yet.
BSX currently screens at market cap $71.81B and trailing P/E 20.2. REPL currently screens at market cap $825.7M.
Not investment advice. Open the BSX and REPL stock pages for the full models.
Not investment advice.